FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 504 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR How Writing Helped Me Cope During Cancer April 27, 2021 KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... March 14, 2023 Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App September 18, 2021 ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Load more HOT NEWS A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and... Self-Dissolving Cracker Makes Swallowing Easier for People Struggling with Dysphagia A Penny for Your Thoughts Woman Helps Students With Special Needs Achieve Success After Graduation
